by Jeremie Oliver
For Utah Business, I’ve covered biotechnology breakthroughs ranging from breast cancer diagnosis to novel intestinal disease therapeutics. But we haven’t yet discussed a disease that is even more prevalent than those combined: Alzheimer’s.
Currently plaguing more than 6 million Americans over the age of 65, Alzheimer’s disease is expected to rise in prevalence by over 100 percent by 2050, reaching around 13 million patients within the United States alone. The US healthcare system currently spends upward of $321 billion on this disease, and those costs are only expected to skyrocket as time passes. As a result, hundreds of millions of research dollars have been allocated to groups worldwide to investigate potential therapeutic targets to disrupt the progression of this insidious pathology.
https://www.utahbusiness.com/heres-how-halia-therapeutics-aims-to-curb-alzheimers-and-more/